Synthetic drugs change fast. Detection can't afford to lag behind.
Haptyco is developing monoclonal antibody reagents and an AI-driven surveillance platform to identify fentanyl analogues and novel psychoactive substances as they emerge — designed to turn a single detection event into an early warning for the people who need it first.
The gap
Reference libraries can't keep pace with the chemistry.
New fentanyl analogues and NPS variants are engineered specifically to slip past existing immunoassays and reference standards.
Confirmatory methods like mass spectrometry are accurate but slow — by the time a substance is characterised, it may already be off the shelf.
Forensic labs, hospitals, and field teams need a first signal in minutes, not a confirmed identification in weeks.
The approach
Two systems, one signal chain.
Monoclonal antibody detection
Purpose-raised antibodies bind emerging fentanyl analogues and NPS structures that generic screening panels miss, giving labs a specific, sensitive first-line reagent rather than a broad, blunt one.
AI-powered surveillance
Detection events feed a pattern-analysis layer that tracks where and how fast new substances are spreading, so agencies see an emerging trend, not just an isolated sample.
The stakes
Speed is the whole point.
Sources: EUDA European Drug Report 2026 · UNODC Early Warning Advisory
How it works
From sample to warning, in one pipeline.
Sample capture
A field or lab sample is introduced to the assay — no specialised equipment required at the point of collection.
Antibody binding
Haptyco's monoclonal antibodies bind their target analogue, producing a measurable signal within minutes.
Signal readout
The result is captured digitally rather than read by eye alone, removing a common source of error and delay.
Pattern analysis
Readouts across sites are aggregated so the platform can distinguish a one-off finding from a spreading pattern.
Early warning
Relevant agencies receive a flag while there is still time to respond — not after the substance is already established.
Who we serve
Built for the teams closest to the problem.
Forensic science laboratories
A fast, specific first-line reagent that narrows down what confirmatory instruments need to characterise.
Public health & addiction services
Population-level signal on which substances are actually circulating, to inform harm-reduction and treatment response.
Law enforcement & border agencies
Field-deployable screening that supports faster, better-informed decisions at the point of encounter.
Why Haptyco
Started from the bench, built for the field.
Haptyco was founded on the premise that drug detection should evolve at the same speed as the chemistry it's trying to catch. The founding team's background is in extracellular vesicle biology, nanoparticle drug delivery, and antibody-based diagnostics — brought to bear on a public health problem that has outrun the tools built to track it.
Haptyco · company in formation
Where we are
Early-stage, and clear about it.
Haptyco is a company in formation — not yet incorporated — with its science at the concept and research stage. It is pre-revenue and pre-product. What exists today is a validated premise and a clear plan; the next steps depend on the right backing and the right people.
You are here — building from the ground up.
Investors
We're raising to move from a proven premise to a working prototype. Early conversations welcome from angels and funds active in diagnostics, health, or public safety.
Start a conversation →Co-founders & team
Looking for scientific and commercial co-founders who want to build this properly from day one — not join once it's already made.
Introduce yourself →Pilot partners
Seeking forensic labs, health services, and agencies open to shaping and testing early work, so the technology is built around real needs.
Explore a pilot →The product visuals and figures on this site illustrate a concept in development. They don't represent a working product, live data, or a service available today.